<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="677a4e72-7b0a-4f6c-b82e-091d93588566"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use <content styleCode="bold">ESMOLOL HYDROCHLORIDE INJECTION</content> safely and effectively.  See full prescribing information for <content styleCode="bold">ESMOLOL HYDROCHLORIDE INJECTION</content>.<br/>  <br/>
      <content styleCode="bold">ESMOLOL HYDROCHLORIDE injection, for intravenous use</content>
      <br/>
      <br/>Initial U.S. Approval: 1986</title>
   <effectiveTime value="20250227"/>
   <setId root="94f069f9-dd52-4a69-a103-ebdb4294f088"/>
   <versionNumber value="11"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="790384502" root="1.3.6.1.4.1.519.1"/>
            <name>Mylan Institutional LLC</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="4deafbb7-7aed-4bbd-8ab0-45cfb9e1cff4"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20170404"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="67457-182" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Esmolol Hydrochloride</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>esmolol hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V05260LC8D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ESMOLOL HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="MDY902UXSR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ESMOLOL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NVG71ZZ7P0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE ANHYDROUS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="67457-182-00" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="67457-182-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20070529"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA076474" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20070529"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_7FA31483-CC1E-4142-9E58-5B7E3076F9EC">
               <id root="a8246f60-99be-41b8-aa3e-90057e6acd03"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <effectiveTime value="20250227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Esmolol hydrochloride injection is a beta adrenergic blocker indicated for the short-term treatment of:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia (<linkHtml href="#ID_0b45d134-ae5d-4168-9149-2e5904c14b9e">1.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Control of perioperative tachycardia and hypertension (<linkHtml href="#ID_f86b59c9-0b88-405c-ab4e-988096727e40">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_0b45d134-ae5d-4168-9149-2e5904c14b9e">
                     <id root="762cfa1c-6e3b-421e-8db5-fcc929e43c58"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia </title>
                     <text>
                        <paragraph>Esmolol hydrochloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride injection is intended for short-term use.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f86b59c9-0b88-405c-ab4e-988096727e40">
                     <id root="cf81639f-cf91-436d-b0ce-e6c2d161f734"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Intraoperative and Postoperative Tachycardia and/or Hypertension </title>
                     <text>
                        <paragraph>Esmolol hydrochloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated.</paragraph>
                        <paragraph>Use of esmolol hydrochloride injection to prevent such events is not recommended. </paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3AB1427F-044B-4D61-A628-22A67D50559F">
               <id root="59910cec-6762-47c8-a6cf-3313e0df5e26"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20250227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Administer intravenously (<linkHtml href="#ID_2dcf54da-ea5d-41a8-94c7-22bca60b94a8">2.1</linkHtml>, <linkHtml href="#ID_4bb1260d-d688-410b-882f-5dbb9fc34e28">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Titrate using ventricular rate or blood pressure at ≥ 4-minute intervals. (<linkHtml href="#ID_2dcf54da-ea5d-41a8-94c7-22bca60b94a8">2.1</linkHtml>, <linkHtml href="#ID_4bb1260d-d688-410b-882f-5dbb9fc34e28">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Supraventricular tachycardia (SVT) or noncompensatory sinus tachycardia (<linkHtml href="#ID_2dcf54da-ea5d-41a8-94c7-22bca60b94a8">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Optional loading dose: 500 mcg per kg infused over one minute</item>
                           <item>
                              <caption>•</caption>Then 50 mcg per kg per minute for the next 4 minutes</item>
                           <item>
                              <caption>•</caption>Adjust dose as needed to a maximum of 200 mcg per kg per minute.</item>
                           <item>
                              <caption>•</caption>Additional loading doses may be administered </item>
                           <item>
                              <caption>•</caption>Perioperative tachycardia and hypertension (<linkHtml href="#ID_4bb1260d-d688-410b-882f-5dbb9fc34e28">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Loading dose: 500 mcg per kg over 1 minute for gradual control (1 mg per kg over 30 seconds for immediate control)</item>
                           <item>
                              <caption>•</caption>Then 50 mcg per kg per min for gradual control (150 mcg per kg per minute for immediate control) adjusted to a maximum of 200 (tachycardia) or 300 (hypertension) mcg per kg per min (<linkHtml href="#ID_4bb1260d-d688-410b-882f-5dbb9fc34e28">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_2dcf54da-ea5d-41a8-94c7-22bca60b94a8">
                     <id root="297d7b3d-4d6d-4dea-b9cf-213d1331c6d4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Dosing for the Treatment of Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia </title>
                     <text>
                        <paragraph>Esmolol hydrochloride injection is administered by continuous intravenous infusion with or without a loading dose. Additional loading doses and/or titration of the maintenance infusion (step-wise dosing) may be necessary based on desired ventricular response.</paragraph>
                        <table width="100%">
                           <caption>Table 1: Step-Wise Dosing</caption>
                           <col width="8%"/>
                           <col width="92%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Step</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Action</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Optional loading dose (500 mcg per kg over 1 minute), then 50 mcg per kg per min for 4 min</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Optional loading dose if necessary, then 100 mcg per kg per min for 4 min</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Optional loading dose if necessary, then 150 mcg per kg per min for 4 min</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>If necessary, increase dose to 200 mcg per kg per min</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In the absence of loading doses, continuous infusion of a single concentration of esmolol reaches pharmacokinetic and pharmacodynamic steady-state in about 30 minutes.</paragraph>
                        <paragraph>The effective maintenance dose for continuous and step-wise dosing is 50 to 200 mcg per kg per minute, although doses as low as 25 mcg per kg per minute have been adequate. Dosages greater than 200 mcg per kg per minute provide little added heart rate lowering effect, and the rate of adverse reactions increases.</paragraph>
                        <paragraph>Maintenance infusions may be continued for up to 48 hours.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_4bb1260d-d688-410b-882f-5dbb9fc34e28">
                     <id root="d7c1c9c2-3024-4a57-8f21-510ece125eb5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Intraoperative and Postoperative Tachycardia and Hypertension </title>
                     <text>
                        <paragraph>In this setting it is not always advisable to slowly titrate to a therapeutic effect. Therefore two dosing options are presented: immediate control and gradual control.</paragraph>
                        <paragraph>Immediate Control</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Administer 1 mg per kg as a bolus dose over 30 seconds followed by an infusion of 150 mcg per kg per min if necessary.</item>
                           <item>
                              <caption>•</caption>Adjust the infusion rate as required to maintain desired heart rate and blood pressure. Refer to Maximum Recommended Doses below.</item>
                        </list>
                        <paragraph>Gradual Control</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Administer 500 mcg per kg as a bolus dose over 1 minute followed by a maintenance infusion of 50 mcg per kg per min for 4 minutes.</item>
                           <item>
                              <caption>•</caption>Depending on the response obtained, continue dosing as outlined for supraventricular tachycardia. Refer to Maximum Recommended Doses below.</item>
                        </list>
                        <paragraph>Maximum Recommended Doses</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>For the treatment of tachycardia, maintenance infusion dosages greater than 200 mcg per kg per min are not recommended; dosages greater than 200 mcg per kg per min provide little additional heart rate-lowering effect, and the rate of adverse reactions increases.</item>
                           <item>
                              <caption>•</caption>For the treatment of hypertension, higher maintenance infusion dosages (250-300 mcg per kg per min) may be required. The safety of doses above 300 mcg per kg per minute has not been studied.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c93d3a35-c07e-4ca4-bdfc-3c925ac07087">
                     <id root="44c62be1-3a56-4f61-8dd1-1f15058c7101"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Transition from Esmolol Hydrochloride Injection Therapy to Alternative Drugs </title>
                     <text>
                        <paragraph>After patients achieve adequate control of the heart rate and a stable clinical status, transition to alternative antiarrhythmic drugs may be accomplished.</paragraph>
                        <paragraph>When transitioning from esmolol hydrochloride injection to alternative drugs, the physician should carefully consider the labeling instructions of the alternative drug selected and reduce the dosage of esmolol hydrochloride injection as follows:</paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Thirty minutes following the first dose of the alternative drug, reduce the esmolol hydrochloride infusion rate by one-half (50%).</item>
                           <item>
                              <caption>2.</caption>After administration of the second dose of the alternative drug, monitor the patient's response and if satisfactory control is maintained for the first hour, discontinue the esmolol hydrochloride infusion.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_71bd3ccd-0ae1-4db4-8fc1-e2158ae4c9a6">
                     <id root="b2a3bb00-c8e0-4bf4-a441-75fbdf27a6fb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Directions for Use </title>
                     <text>
                        <paragraph>Esmolol hydrochloride injection is available in a single-dose vial. Esmolol hydrochloride injection is not compatible with Sodium Bicarbonate (5%) solution (limited stability) or furosemide (precipitation).</paragraph>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
                        <paragraph>Discard unused portion.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                     <component>
                        <section ID="ID_291d512f-4a28-4cc3-bca4-2f59ec83a2b9">
                           <id root="076b6fda-63ca-43f6-bdbc-b2b02b2b1b46"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Single-Dose Vial</content>
                              </content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>The single-dose vial may be used to administer a loading dosage by hand-held syringe while the maintenance infusion is being prepared.</paragraph>
                           </text>
                           <effectiveTime value="20170404"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6B226C5E-9D67-4F46-BAFC-076901F8F51F">
               <id root="a501014f-a503-40b4-b12e-2aaf62383531"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <table width="100%">
                     <caption>Table 2: Esmolol Hydrochloride Injection Presentation</caption>
                     <col width="50%"/>
                     <col width="50%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>Product Name</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>Esmolol Hydrochloride Injection</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Total Dose</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>100 mg/10 mL</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Esmolol Hydrochloride Concentration</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                              <paragraph>10 mg/mL</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>Packaging</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>10 mL Single-Dose Vial</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 100 mg/10 mL (10 mg/mL) in 10 mL single-dose vial (<linkHtml href="#ID_6B226C5E-9D67-4F46-BAFC-076901F8F51F">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_220166CD-6EAB-499B-B456-39F989A6E7CC">
               <id root="66176dbb-929d-4daa-93e0-650dde6befe8"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>Esmolol hydrochloride injection is contraindicated in patients with:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Severe sinus bradycardia: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest <content styleCode="italics">[see <linkHtml href="#ID_9b340d91-e448-4d8c-b6f0-84a07633538f">Warnings and Precautions (5.2)</linkHtml>]</content>.</item>
                     <item>
                        <caption>•</caption>Heart block greater than first degree: Second- or third-degree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest <content styleCode="italics">[see <linkHtml href="#ID_9b340d91-e448-4d8c-b6f0-84a07633538f">Warnings and Precautions (5.2)</linkHtml>]</content>.</item>
                     <item>
                        <caption>•</caption>Sick sinus syndrome: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest <content styleCode="italics">[see <linkHtml href="#ID_9b340d91-e448-4d8c-b6f0-84a07633538f">Warnings and Precautions (5.2)</linkHtml>]</content>.</item>
                     <item>
                        <caption>•</caption>Decompensated heart failure: May worsen heart failure.</item>
                     <item>
                        <caption>•</caption>Cardiogenic shock: May precipitate further cardiovascular collapse and cause cardiac arrest.</item>
                     <item>
                        <caption>•</caption>IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and esmolol hydrochloride injection in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving esmolol hydrochloride injection and intravenous verapamil.</item>
                     <item>
                        <caption>•</caption>Pulmonary hypertension: May precipitate cardiorespiratory compromise.</item>
                     <item>
                        <caption>•</caption>Hypersensitivity reactions, including anaphylaxis, to esmolol or any of the inactive ingredients of the product (cross-sensitivity between beta blockers is possible).</item>
                  </list>
               </text>
               <effectiveTime value="20230915"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Severe sinus bradycardia (<linkHtml href="#ID_220166CD-6EAB-499B-B456-39F989A6E7CC">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Heart block greater than first degree (<linkHtml href="#ID_220166CD-6EAB-499B-B456-39F989A6E7CC">4</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Sick sinus syndrome (<linkHtml href="#ID_220166CD-6EAB-499B-B456-39F989A6E7CC">4</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Decompensated heart failure (<linkHtml href="#ID_220166CD-6EAB-499B-B456-39F989A6E7CC">4</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Cardiogenic shock (<linkHtml href="#ID_220166CD-6EAB-499B-B456-39F989A6E7CC">4</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Coadministration of IV cardiodepressant calcium-channel antagonists (e.g. verapamil) in close proximity to esmolol hydrochloride injection (<linkHtml href="#ID_220166CD-6EAB-499B-B456-39F989A6E7CC">4</linkHtml>, <linkHtml href="#ID_6CE1D822-AFFF-4A1E-B41B-61CE87D7F5D5">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Pulmonary hypertension (<linkHtml href="#ID_220166CD-6EAB-499B-B456-39F989A6E7CC">4</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Known hypersensitivity to esmolol (<linkHtml href="#ID_220166CD-6EAB-499B-B456-39F989A6E7CC">4</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_C624C382-D4BB-4EB0-9E1D-54BEB0D5A913">
               <id root="d60f7bee-2164-4b27-941e-14267938bb51"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20250227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Risk of hypotension, bradycardia, and cardiac failure: Monitor for signs and symptoms of cardiovascular adverse effects. Reduce or discontinue use (<linkHtml href="#ID_dba783fc-4921-434a-a41c-911ae69052bb">5.1</linkHtml>, <linkHtml href="#ID_9b340d91-e448-4d8c-b6f0-84a07633538f">5.2</linkHtml>, <linkHtml href="#ID_e7ba307e-7a66-411e-b171-9cd797f2a467">5.3</linkHtml>, <linkHtml href="#ID_d023f798-21a9-46f8-a58c-9b365b680103">5.10</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Risk of exacerbating reactive airway disease (<linkHtml href="#ID_9625ad22-7cdc-4409-91bc-f054784e050d">5.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Diabetes: May mask symptoms of hypoglycemia and alter glucose levels; monitor (<linkHtml href="#ID_388a6243-25d3-4a74-802e-fdb1463884b4">5.6</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Risk of unopposed alpha-agonism and severe hypertension in untreated pheochromocytoma (<linkHtml href="#ID_b052851a-b17a-4d39-a75d-e9db83ca98c9">5.9</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Risk of myocardial ischemia when abruptly discontinued in patients with coronary artery disease (<linkHtml href="#ID_5792c4c2-059f-4311-ab5b-5851762bc864">5.12</linkHtml>, <linkHtml href="#ID_07bb1da0-d094-4254-b729-4387b5218715">5.15</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_dba783fc-4921-434a-a41c-911ae69052bb">
                     <id root="f758d842-b287-45d1-ae0d-9d944ad2ca04"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypotension </title>
                     <text>
                        <paragraph>Hypotension can occur at any dose but is dose-related. Patients with hemodynamic compromise or on interacting medications are at particular risk. Severe reactions may include loss of consciousness, cardiac arrest, and death. For control of ventricular heart rate, maintenance doses greater than 200 mcg per kg per min are not recommended. Monitor patients closely, especially if pretreatment blood pressure is low. In case of an unacceptable drop in blood pressure, reduce or stop esmolol hydrochloride injection. Decrease of dose or termination of infusion reverses hypotension, usually within 30 minutes.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9b340d91-e448-4d8c-b6f0-84a07633538f">
                     <id root="ee606f91-885f-4109-8446-91fec06a2d6b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Bradycardia </title>
                     <text>
                        <paragraph>Bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest have occurred with the use of esmolol hydrochloride injection. Patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders may be at increased risk. Monitor heart rate and rhythm in patients receiving esmolol hydrochloride injection<content styleCode="italics"> [see <linkHtml href="#ID_220166CD-6EAB-499B-B456-39F989A6E7CC">Contraindications (4)</linkHtml>]</content>.</paragraph>
                        <paragraph>If severe bradycardia develops, reduce or stop esmolol hydrochloride injection.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e7ba307e-7a66-411e-b171-9cd797f2a467">
                     <id root="5d5d218b-0f80-476e-b25b-efba92392308"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Cardiac Failure </title>
                     <text>
                        <paragraph>Beta blockers, like esmolol hydrochloride injection, can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock. At the first sign or symptom of impending cardiac failure, stop esmolol hydrochloride injection and start supportive therapy <content styleCode="italics">[see <linkHtml href="#ID_AF0EFC0F-7E64-4E82-917A-2564916D8C32">Overdosage (10)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_491b58ff-d9f1-4c32-8853-3cd46860c815">
                     <id root="4673e4da-501c-48f1-91ba-2e9ecaa83932"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Intraoperative and Postoperative Tachycardia and/or Hypertension </title>
                     <text>
                        <paragraph>Monitor vital signs closely and titrate esmolol hydrochloride injection slowly in the treatment of patients whose blood pressure is primarily driven by vasoconstriction associated with hypothermia.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9625ad22-7cdc-4409-91bc-f054784e050d">
                     <id root="6d1b7942-f4db-4cb2-974f-db198e428ad0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Reactive Airways Disease </title>
                     <text>
                        <paragraph>Patients with reactive airways disease should, in general, not receive beta blockers. Because of its relative beta<sub>1</sub> selectivity and titratability, titrate esmolol hydrochloride injection to the lowest possible effective dose. In the event of bronchospasm, stop the infusion immediately; a beta<sub>2</sub> stimulating agent may be administered with appropriate monitoring of ventricular rates.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_388a6243-25d3-4a74-802e-fdb1463884b4">
                     <id root="11ffae31-ac24-493d-9efb-5e2c01b341bf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Hypoglycemia </title>
                     <text>
                        <paragraph>Beta-blockers may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia at any time during treatment, especially in patients with diabetes mellitus or children and patients who are fasting (i.e., surgery, not eating regularly, or are vomiting). If severe hypoglycemia occurs, patients should be instructed to seek emergency treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_644ea481-0066-45b0-86ab-2ad5b86e7cd1">
                     <id root="0b4a5d2a-06e7-4e40-a679-e55e98c3f8f6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Infusion Site Reactions </title>
                     <text>
                        <paragraph>Infusion site reactions have occurred with the use of esmolol hydrochloride injection. They include irritation, inflammation, and severe reactions (thrombophlebitis, necrosis, and blistering), in particular when associated with extravasation <content styleCode="italics">[see <linkHtml href="#ID_C5B65FB2-53AD-48B0-AEF3-4F2F94A5AEEE">Adverse Reactions (6)</linkHtml>]</content>. Avoid infusions into small veins or through a butterfly catheter.</paragraph>
                        <paragraph>If a local infusion site reaction develops, use an alternative infusion site and avoid extravasation.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5dbe237d-4ee8-4b41-a568-758e17f39b6a">
                     <id root="a70a6ebe-ce4e-41c5-8f0c-a5bbe56a5472"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Use in Patients with Prinzmetal’s Angina </title>
                     <text>
                        <paragraph>Beta blockers may exacerbate anginal attacks in patients with Prinzmetal’s angina because of unopposed alpha receptor–mediated coronary artery vasoconstriction. Do not use nonselective beta blockers.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b052851a-b17a-4d39-a75d-e9db83ca98c9">
                     <id root="42715d27-fd9e-491c-b1fe-44731741067f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Use in Patients with Pheochromocytoma </title>
                     <text>
                        <paragraph>If esmolol hydrochloride injection is used in the setting of pheochromocytoma, give it in combination with an alpha-blocker, and only after the alpha-blocker has been initiated. Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure from the attenuation of beta-mediated vasodilation in skeletal muscle.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d023f798-21a9-46f8-a58c-9b365b680103">
                     <id root="11cf979f-a73f-4642-84ee-7d906dfd09aa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Use in Hypovolemic Patients </title>
                     <text>
                        <paragraph>In hypovolemic patients, esmolol hydrochloride injection can attenuate reflex tachycardia and increase the risk of hypotension.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_fda5cbc9-dc10-4b60-ab09-a072400f2ab6">
                     <id root="badd3c42-7a4f-4399-a0b6-0fa36c549185"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Use in Patients with Peripheral Circulatory Disorders </title>
                     <text>
                        <paragraph>In patients with peripheral circulatory disorders (including Raynaud’s disease or syndrome, and peripheral occlusive vascular disease), esmolol hydrochloride injection may aggravate peripheral circulatory disorders.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5792c4c2-059f-4311-ab5b-5851762bc864">
                     <id root="78f9b4de-309f-4513-be0c-7db8753f9b6f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Abrupt Discontinuation of Esmolol Hydrochloride Injection </title>
                     <text>
                        <paragraph>Severe exacerbations of angina, myocardial infarction, and ventricular arrhythmias have been reported in patients with coronary artery disease upon abrupt discontinuation of beta blocker therapy. Observe patients for signs of myocardial ischemia when discontinuing esmolol hydrochloride injection.</paragraph>
                        <paragraph>Heart rate increases moderately above pretreatment levels 30 minutes after esmolol hydrochloride injection discontinuation.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_66e3f677-fd36-445d-98d0-1e0165b06d8b">
                     <id root="8299a9fc-d0a2-454a-a9e1-d2052c8e9100"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Hyperkalemia </title>
                     <text>
                        <paragraph>Beta blockers, including esmolol hydrochloride injection, have been associated with increases in serum potassium levels and hyperkalemia. The risk is increased in patients with risk factors such as renal impairment. Intravenous administration of beta blockers has been reported to cause potentially life-threatening hyperkalemia in hemodialysis patients. Monitor serum electrolytes during therapy with esmolol hydrochloride injection.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d841594d-3ff6-48d6-accf-4c550baab770">
                     <id root="988e45f4-a056-4b43-8704-2db9160cd258"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.14 Use in Patients with Metabolic Acidosis </title>
                     <text>
                        <paragraph>Beta blockers, including esmolol hydrochloride injection, have been reported to cause hyperkalemic renal tubular acidosis. Acidosis in general may be associated with reduced cardiac contractility.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_07bb1da0-d094-4254-b729-4387b5218715">
                     <id root="1b80106f-3e3d-441a-b8e5-5badb4505063"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.15 Use in Patients with Hyperthyroidism </title>
                     <text>
                        <paragraph>Beta-adrenergic blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, monitor patients for signs of thyrotoxicosis when withdrawing beta blocking therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ab8ea8a7-ae9b-4cc6-aa2a-e01c62049622">
                     <id root="d6c5969d-3255-43ea-9a22-b1da42576c14"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.16 Use in Patients at Risk of Severe Acute Hypersensitivity Reactions </title>
                     <text>
                        <paragraph>When using beta blockers, patients at risk of anaphylactic reactions may be more reactive to allergen exposure (accidental, diagnostic, or therapeutic).</paragraph>
                        <paragraph>Patients using beta blockers may be unresponsive to the usual doses of epinephrine used to treat anaphylactic or anaphylactoid reactions <content styleCode="italics">[see <linkHtml href="#ID_6CE1D822-AFFF-4A1E-B41B-61CE87D7F5D5">Drug Interactions (7)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_C5B65FB2-53AD-48B0-AEF3-4F2F94A5AEEE">
               <id root="99835886-ac19-4b23-a56a-c911075558f4"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <effectiveTime value="20250227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence &gt; 10%) are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension (<linkHtml href="#ID_C5B65FB2-53AD-48B0-AEF3-4F2F94A5AEEE">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Mylan at 1-877-446-3679 (1-877-4-INFO-RX)</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_8e5ba8ba-a554-480d-a05e-041959f8cb8a">
                     <id root="ca2a64cd-a2b3-46ae-9cd9-2443a4b957a7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>The following adverse reaction rates are based on use of esmolol hydrochloride injection in clinical trials involving 369 patients with supraventricular tachycardia and over 600 intraoperative and postoperative patients enrolled in clinical trials. Most adverse effects observed in controlled clinical trial settings have been mild and transient. The most important and common adverse effect has been hypotension <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#ID_dba783fc-4921-434a-a41c-911ae69052bb">Warnings and Precautions (5.1)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>. Deaths have been reported in post-marketing experience occurring during complex clinical states where esmolol hydrochloride injection was presumably being used simply to control ventricular rate <content styleCode="italics">[see <linkHtml href="#ID_9625ad22-7cdc-4409-91bc-f054784e050d">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                        <table width="100%">
                           <caption>Table 3: Clinical Trial Adverse Reactions (Frequency ≥ 3%)</caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">System Organ Class (SOC)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Preferred MedDRA Term</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Frequency</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>VASCULAR DISORDERS</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Hypotension<footnote ID="_Ref486494007">Hypotension resolved during esmolol hydrochloride infusion in 63% of patients. In 80% of the remaining patients, hypotension resolved within 30 minutes following discontinuation of infusion.</footnote>
                                    </paragraph>
                                    <paragraph>   Asymptomatic hypotension </paragraph>
                                    <paragraph>   Symptomatic hypotension (hyperhidrosis, dizziness)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph> </paragraph>
                                    <paragraph>25%</paragraph>
                                    <paragraph>12%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Infusion site reactions </paragraph>
                                    <paragraph>(inflammation and induration)</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>8%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>GASTROINTESTINAL DISORDERS</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>7%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>NERVOUS SYSTEM DISORDERS</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Dizziness</paragraph>
                                 </td>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Somnolence</paragraph>
                                 </td>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>3%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Clinical Trial Adverse Reactions (Frequency &lt; 3%):</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders:</content>
                        </paragraph>
                        <paragraph>Confusional state and agitation (~2%)<br/>Anxiety, depression and abnormal thinking (&lt; 1%)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders:</content>
                        </paragraph>
                        <paragraph>Headache (~2%)<br/>Paresthesia, syncope, speech disorder, and lightheadedness (&lt; 1%)<br/>Convulsions (&lt; 1%), with one death</paragraph>
                        <paragraph>
                           <content styleCode="italics">Vascular Disorders:</content>
                        </paragraph>
                        <paragraph>Peripheral ischemia (~1%)<br/>Pallor and flushing (&lt; 1%)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal Disorders:</content>
                        </paragraph>
                        <paragraph>Vomiting (~1%)<br/>Dyspepsia, constipation, dry mouth, and abdominal discomfort (&lt; 1%)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal and Urinary Disorders:</content>
                        </paragraph>
                        <paragraph>Urinary retention (&lt; 1%)</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_fc3a146b-0b6f-4feb-ac02-dd1ca3abc854">
                     <id root="fb4e5090-bdee-4c44-8495-8467ad0bad56"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Post-Marketing Experience </title>
                     <text>
                        <paragraph>In addition to the adverse reactions reported in clinical trials, the following adverse reactions have been reported in the post-marketing experience. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or to establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiac Disorders: </content>
                        </paragraph>
                        <paragraph>Cardiac arrest, Coronary arteriospasm </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders: </content>
                        </paragraph>
                        <paragraph>Angioedema, Urticaria, Psoriasis</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6CE1D822-AFFF-4A1E-B41B-61CE87D7F5D5">
               <id root="e03d1baa-04ed-4ad3-803a-0f0cf734ed4f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <text>
                  <paragraph>Concomitant use of esmolol hydrochloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride injection’s effects on blood pressure, contractility, and impulse propagation. Severe interactions with such drugs can result in, for example, severe hypotension, cardiac failure, severe bradycardia, sinus pause, sinoatrial block, atrioventricular block, and/or cardiac arrest. In addition, with some drugs, beta blockade may precipitate increased withdrawal effects. (See clonidine, guanfacine, and moxonidine below.) Esmolol hydrochloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride injection leads to an approximate 10% to 20% increase of digoxin blood levels at some time points. Digoxin does not affect esmolol hydrochloride injection pharmacokinetics. Both digoxin and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use increases the risk of bradycardia.</item>
                     <item>
                        <caption>•</caption>Anticholinesterases: Esmolol hydrochloride injection prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium.</item>
                     <item>
                        <caption>•</caption>Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. If, during concomitant use of a beta blocker, antihypertensive therapy needs to be interrupted or discontinued, discontinue the beta blocker first, and the discontinuation should be gradual.</item>
                     <item>
                        <caption>•</caption>Calcium channel antagonists: In patients with depressed myocardial function, use of esmolol hydrochloride injection with cardiodepressant calcium channel antagonists (e.g., verapamil) can lead to fatal cardiac arrests.</item>
                     <item>
                        <caption>•</caption>Sympathomimetic drugs: Sympathomimetic drugs having beta-adrenergic agonist activity will counteract effects of esmolol hydrochloride injection.</item>
                     <item>
                        <caption>•</caption>Vasoconstrictive and positive inotropic agents: Because of the risk of reducing cardiac contractility in presence of high systemic vascular resistance, do not use esmolol hydrochloride injection to control tachycardia in patients receiving drugs that are vasoconstrictive and have positive inotropic effects, such as epinephrine, norepinephrine, and dopamine.</item>
                  </list>
               </text>
               <effectiveTime value="20230915"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Digitalis glycosides: Risk of bradycardia (<linkHtml href="#ID_6CE1D822-AFFF-4A1E-B41B-61CE87D7F5D5">7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Anticholinesterases: Prolongs neuromuscular blockade (<linkHtml href="#ID_6CE1D822-AFFF-4A1E-B41B-61CE87D7F5D5">7</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Antihypertensive agents: Risk of rebound hypertension (<linkHtml href="#ID_6CE1D822-AFFF-4A1E-B41B-61CE87D7F5D5">7</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Sympathomimetic drugs: Dose adjustment needed (<linkHtml href="#ID_6CE1D822-AFFF-4A1E-B41B-61CE87D7F5D5">7</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Vasoconstrictive and positive inotropic effect substances: Avoid concomitant use (<linkHtml href="#ID_6CE1D822-AFFF-4A1E-B41B-61CE87D7F5D5">7</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_4EC97F3B-09A1-405F-9D03-A8EE5AF5901B">
               <id root="04392129-bba7-49e5-a1df-fbc0b5adbe3a"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20250227"/>
               <component>
                  <section ID="ID_92BF629F-DC78-4017-9FF6-7D2307C2EA2D">
                     <id root="2fe41547-744f-459a-8062-6a09ba74e59a"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>Esmolol hydrochloride has been shown to produce increased fetal resorptions with minimal maternal toxicity in rabbits when given in doses approximately 8 times the maximum human maintenance dose (300 mcg/kg/min). There are no adequate and well-controlled studies in pregnant women. Esmolol hydrochloride injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                        <paragraph>Teratogenicity studies in rats at intravenous dosages of esmolol hydrochloride up to 3000 mcg/kg/min (10 times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while a dosage of 10,000 mcg/kg/min produced maternal toxicity and lethality. In rabbits, intravenous dosages up to 1000 mcg/kg/min for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while 2500 mcg/kg/min produced minimal maternal toxicity and increased fetal resorptions.</paragraph>
                     </text>
                     <effectiveTime value="20230915"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_18E15BBE-D944-4C29-8F19-D711E108E863">
                     <id root="88b0a5f4-03d7-4b41-af75-7cc33c51fae4"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Labor and Delivery </title>
                     <text>
                        <paragraph>Although there are no adequate and well-controlled studies in pregnant women, use of esmolol in the last trimester of pregnancy or during labor or delivery has been reported to cause fetal bradycardia, which continued after termination of drug infusion. Esmolol hydrochloride injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                     </text>
                     <effectiveTime value="20230915"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_DC006848-F7B5-44E1-930F-EAC13E41FAA7">
                     <id root="a92b369f-f43a-4a3e-bfda-b172ee2343d5"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers </title>
                     <text>
                        <paragraph>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from esmolol hydrochloride injection, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20230915"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6BB06BC7-E7CF-409A-B75B-EA271D564474">
                     <id root="0a877ce0-a3b0-4c85-a5d2-74ec2284769c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness of esmolol hydrochloride injection in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20230915"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2E1B6AA1-11B1-4E2E-AA87-44E4DCCCFAC4">
                     <id root="e6408ed9-98d4-494b-9bb0-c4934c7b3a89"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Clinical studies of esmolol hydrochloride injection did not include sufficient numbers of subjects aged 65 and over to determine whether they responded differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should usually start at the low end of the dosing range, reflecting greater frequency of decreased renal or cardiac function and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20230915"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b339c75f-4b63-4d19-bd74-86010dba88cd">
                     <id root="732740d2-747e-4660-9674-df94d6b01a17"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment </title>
                     <text>
                        <paragraph>No special precautions are necessary in patients with hepatic impairment because esmolol hydrochloride injection is metabolized by red-blood cell esterases <content styleCode="italics">[see <linkHtml href="#ID_78C20495-ADFA-4A74-9743-716CA9D6E883">Clinical Pharmacology (12)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9584b759-aa48-4a90-a6c4-a13c540cced4">
                     <id root="203083d0-cc74-4242-a933-4752e7eb540a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Renal Impairment </title>
                     <text>
                        <paragraph>No dosage adjustment is required for esmolol in patients with renal impairment receiving a maintenance infusion of esmolol 150 mcg/kg for 4 hours. There is no information on the tolerability of maintenance infusions of esmolol using rates in excess of 150 mcg/kg or maintained longer than 4 hours <content styleCode="italics">[see <linkHtml href="#ID_78C20495-ADFA-4A74-9743-716CA9D6E883">Clinical Pharmacology (12)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_AF0EFC0F-7E64-4E82-917A-2564916D8C32">
               <id root="793a55da-198c-4402-ba5e-0ab33941f5b8"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <effectiveTime value="20250227"/>
               <component>
                  <section ID="ID_5e9e55f9-d295-4426-b3f5-8df46072d918">
                     <id root="04876f4d-217f-463f-8ec2-efd88b25ecc8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.1 Signs and Symptoms of Overdose </title>
                     <text>
                        <paragraph>Overdoses of esmolol hydrochloride injection can cause cardiac and central nervous system effects. These effects may precipitate severe signs, symptoms, sequelae, and complications (for example, severe cardiac and respiratory failure, including shock and coma), and may be fatal. Continuous monitoring of the patient is required.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Cardiac effects include bradycardia, atrioventricular block (1<sup>st</sup> -, 2<sup>nd</sup> -, 3<sup>rd</sup> degree), junctional rhythms, intraventricular conduction delays, decreased cardiac contractility, hypotension, cardiac failure (including cardiogenic shock), cardiac arrest/asystole, and pulseless electrical activity.</item>
                           <item>
                              <caption>•</caption>Central nervous system effects include respiratory depression, seizures, sleep and mood disturbances, fatigue, lethargy, and coma.</item>
                           <item>
                              <caption>•</caption>In addition, bronchospasm, mesenteric ischemia, peripheral cyanosis, hyperkalemia, and hypoglycemia (especially in children) may occur.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_55d5b7d8-6f68-4c4b-8422-187bc29a928a">
                     <id root="b80f7a56-5e29-4cfe-b8e5-558091368cee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.2 Treatment Recommendations </title>
                     <text>
                        <paragraph>Because of its approximately 9-minute elimination half-life, the first step in the management of toxicity should be to discontinue the esmolol hydrochloride infusion. Then, based on the observed clinical effects, consider the following general measures.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                     <component>
                        <section ID="ID_7ff2bc28-f0f5-40f1-b89a-d603e5bc3251">
                           <id root="202db5ad-dd6d-4268-8f32-b7b7517777cd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Bradycardia</content>
                              </content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Consider intravenous administration of atropine or another anticholinergic drug or cardiac pacing.</paragraph>
                           </text>
                           <effectiveTime value="20170404"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_d3f4b741-f89a-4d88-880c-f76dc039bf8d">
                           <id root="8a0c14e8-ab05-431d-b25a-449f860956fd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Cardiac Failure</content>
                              </content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Consider intravenous administration of a diuretic or digitalis glycoside. In shock resulting from inadequate cardiac contractility, consider intravenous administration of dopamine, dobutamine, isoproterenol, or inamrinone. Glucagon has been reported to be useful.</paragraph>
                           </text>
                           <effectiveTime value="20170404"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_1c612871-e573-459b-a724-1ca6e5ac2c56">
                           <id root="0252a055-a2ba-42d4-bf7c-2af189025abe"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Symptomatic Hypotension</content>
                              </content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Consider intravenous administration of fluids or vasopressor agents such as dopamine or norepinephrine.</paragraph>
                           </text>
                           <effectiveTime value="20170404"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_cae15d5a-c07e-4bd6-b41c-09a61cf50983">
                           <id root="6710475b-7e08-4f4b-8d24-e2443212763b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Bronchospasm</content>
                              </content>
                              <content styleCode="bold">
                                 <content styleCode="italics"/>
                              </content>
                           </title>
                           <text>
                              <paragraph>Consider intravenous administration of a beta<sub>2</sub> stimulating agent or a theophylline derivative.</paragraph>
                           </text>
                           <effectiveTime value="20200815"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_9a14f336-845a-447a-a73b-41e618e654f4">
                     <id root="392c5d5d-412d-4cf8-a124-b315fc4715a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.3 Dilution Errors </title>
                     <text>
                        <paragraph>Massive accidental overdoses of esmolol hydrochloride injection have resulted from dilution errors. Some of these overdoses have been fatal while others resulted in permanent disability. Bolus doses in the range of 625 mg to 2.5 g (12.5-50 mg/kg) have been fatal. Patients have recovered completely from overdoses as high as 1.75 g given over one minute or doses of 7.5 g given over one hour for cardiovascular surgery. The patients who survived appear to be those whose circulation could be supported until the effects of esmolol hydrochloride injection resolved. </paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8346FB23-D8EE-4180-ADEF-2EAF3F3F0CB3">
               <id root="776d6f58-ff3f-4408-b88a-b9d297558fa1"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Esmolol hydrochloride injection is a beta adrenergic receptor blocker with a very short duration of action (elimination half-life is approximately 9 minutes). Esmolol hydrochloride is:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>(±)-Methyl p-[2-hydroxy-3-(isopropylamino) propoxy] hydrocinnamate hydrochloride and has the following structure:</item>
                  </list>
                  <renderMultiMedia ID="id-906306431" referencedObject="CC2835C8-6F8B-4841-8F75-39B8590ED149"/>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Esmolol hydrochloride has the molecular formula C<sub>16</sub>H<sub>26</sub>NO<sub>4</sub>Cl and a molecular weight of 331.8. It has one asymmetric center and exists as an enantiomeric pair.</item>
                     <item>
                        <caption>•</caption>Esmolol hydrochloride, USP is a white to off-white crystalline powder. It is a relatively hydrophilic compound which is very soluble in water and freely soluble in alcohol. Its partition coefficient (octanol/water) at pH 7.0 is 0.42 compared to 17.0 for propranolol.</item>
                  </list>
               </text>
               <effectiveTime value="20250227"/>
               <component>
                  <section ID="ID_1036b5d2-b7ec-4ada-9e79-46b0f687ab35">
                     <id root="53b2fea3-9558-468b-9ef7-63c9ece067e8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>11.1 Esmolol Hydrochloride Injection Dosage Forms </title>
                     <text>
                        <paragraph>Esmolol hydrochloride injection is a clear, colorless to light yellow, sterile, nonpyrogenic solution of esmolol hydrochloride. The formulation for esmolol hydrochloride injection is described in the table below:</paragraph>
                        <table width="100%">
                           <caption>Table 4: Esmolol Hydrochloride Injection Formulation</caption>
                           <col width="50%"/>
                           <col width="50%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="2" valign="top">Q.S. = Quantity sufficient</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top"/>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Esmolol Hydrochloride Injection</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Esmolol Hydrochloride, USP</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>10 mg/mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Water for Injection, USP</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Q.S. to volume of 10 mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Sodium Acetate Anhydrous, USP</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>1.688 mg/mL (equivalent to 2.8 mg/mL Sodium Acetate Trihydrate)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Glacial Acetic Acid, USP</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>0.546 mg/mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Sodium Hydroxide</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>Q.S. to adjust pH to 4.5 to 5.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Hydrochloric Acid</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>Q.S. to adjust pH to 4.5 to 5.5</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="CC2835C8-6F8B-4841-8F75-39B8590ED149">
                     <text>Esmolol Hydrochloride Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_78C20495-ADFA-4A74-9743-716CA9D6E883">
               <id root="a7c65d66-e763-4ce0-b351-cc7888fc49b4"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20230915"/>
               <component>
                  <section ID="ID_33464527-3546-42CA-86C2-F82A5CE1C7EF">
                     <id root="051635f9-5ebc-4560-9333-85221a6e29e6"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Esmolol hydrochloride injection is a beta<sub>1</sub>-selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes. Esmolol hydrochloride injection inhibits the beta<sub>1</sub> receptors located chiefly in cardiac muscle, but this preferential effect is not absolute and at higher doses it begins to inhibit beta<sub>2</sub> receptors located chiefly in the bronchial and vascular musculature.</paragraph>
                     </text>
                     <effectiveTime value="20230915"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_EE0B8479-8D50-46AC-B581-FFF462F2CC76">
                     <id root="f25263ac-4968-4e25-af1e-ff54c8208a04"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>Clinical pharmacology studies in normal volunteers have confirmed the beta blocking activity of esmolol hydrochloride injection, showing reduction in heart rate at rest and during exercise, and attenuation of isoproterenol-induced increases in heart rate. Blood levels of esmolol hydrochloride injection have been shown to correlate with extent of beta blockade. After termination of infusion, substantial recovery from beta blockade is observed in 10-20 minutes. The acid metabolite of esmolol exhibits negligible pharmacological activity.</paragraph>
                        <paragraph>In human electrophysiology studies, esmolol hydrochloride injection produced effects typical of a beta blocker: a decrease in the heart rate, increase in sinus cycle length, prolongation of the sinus node recovery time, prolongation of the AH interval during normal sinus rhythm and during atrial pacing, and an increase in antegrade Wenckebach cycle length.</paragraph>
                        <paragraph>In patients undergoing radionuclide angiography, esmolol hydrochloride injection, at dosages of 200 mcg/kg/min, produced reductions in heart rate, systolic blood pressure, rate pressure product, left and right ventricular ejection fraction and cardiac index at rest, which were similar in magnitude to those produced by intravenous propranolol (4 mg). During exercise, esmolol hydrochloride injection produced reductions in heart rate, rate pressure product and cardiac index which were also similar to those produced by propranolol, but esmolol hydrochloride injection produced a significantly larger fall in systolic blood pressure. In patients undergoing cardiac catheterization, the maximum therapeutic dose of 300 mcg/kg/min of esmolol hydrochloride injection produced similar effects and, in addition, there were small, clinically insignificant increases in the left ventricular end diastolic pressure and pulmonary capillary wedge pressure. At 30 minutes after the discontinuation of esmolol hydrochloride infusion, all of the hemodynamic parameters had returned to pretreatment levels.</paragraph>
                        <paragraph>The relative cardioselectivity of esmolol hydrochloride injection was demonstrated in 10 mildly asthmatic patients. Infusions of esmolol hydrochloride injection 100, 200 and 300 mcg/kg/min produced no significant increases in specific airway resistance compared to placebo. At 300 mcg/kg/min, esmolol hydrochloride injection produced slightly enhanced bronchomotor sensitivity to dry air stimulus. These effects were not clinically significant, and esmolol hydrochloride injection was well tolerated by all patients. Six of the patients also received intravenous propranolol, and at a dosage of 1 mg, two experienced significant, symptomatic bronchospasm requiring bronchodilator treatment. One other propranolol-treated patient also experienced dry air-induced bronchospasm. No adverse pulmonary effects were observed in patients with COPD who received therapeutic dosages of esmolol hydrochloride injection for treatment of supraventricular tachycardia (51 patients) or in perioperative settings (32 patients).</paragraph>
                     </text>
                     <effectiveTime value="20230915"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_63A98451-0318-4CE6-8F16-377D20307A03">
                     <id root="890a7417-7094-45d2-a461-5bd89ef0e8b4"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>Esmolol is rapidly metabolized by hydrolysis of the ester linkage, chiefly by the esterases in the cytosol of red blood cells and not by plasma cholinesterases or red cell membrane acetylcholinesterase. Total body clearance in man was found to be about 20 L/kg/hr, which is greater than cardiac output; thus the metabolism of esmolol is not limited by the rate of blood flow to metabolizing tissues such as the liver or affected by hepatic or renal blood flow. Esmolol has a rapid distribution half-life of about 2 minutes and an elimination half-life of about 9 minutes.</paragraph>
                        <paragraph>Using an appropriate loading dose, steady-state blood levels of esmolol hydrochloride injection for dosages from 50-300 mcg/kg/min are obtained within five minutes. Steady-state is reached in about 30 minutes without the loading dose. Steady-state blood levels of esmolol increase linearly over this dosage range and elimination kinetics are dose-independent over this range. Steady-state blood levels are maintained during infusion but decrease rapidly after termination of the infusion. Because of its short half-life, blood levels of esmolol can be rapidly altered by increasing or decreasing the infusion rate and rapidly eliminated by discontinuing the infusion.</paragraph>
                        <paragraph>Consistent with the high rate of blood-based metabolism of esmolol, less than 2% of the drug is excreted unchanged in the urine. Within 24 hours of the end of infusion, the acid metabolite of esmolol in urine accounts for approximately 73-88% of the dosage.</paragraph>
                        <paragraph>Metabolism of esmolol results in the formation of the corresponding free acid and methanol. The acid metabolite has been shown in animals to have negligible activity and in normal volunteers its blood levels do not correspond to the level of beta blockade. The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate. After a 4 hour maintenance infusion of 150 mcg/kg, the plasma concentrations of esmolol are similar in subjects with normal renal function and in patients with ESRD on dialysis. The half-life of the acid metabolite of esmolol hydrochloride injection, which is primarily excreted unchanged by the kidney, is increased about 12-fold to 48 hours in patients with ESRD. The peak concentrations of the acid metabolite are doubled in ESRD.</paragraph>
                        <paragraph>Methanol blood levels, monitored in subjects receiving esmolol hydrochloride injection for up to 6 hours at 300 mcg/kg/min and 24 hours at 150 mcg/kg/min, approximated endogenous levels and were less than 2% of levels usually associated with methanol toxicity.</paragraph>
                        <paragraph>Esmolol hydrochloride injection has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.</paragraph>
                     </text>
                     <effectiveTime value="20230915"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_DF04B9E7-EFAE-452D-9C70-01B9BE137A34">
               <id root="7e830aaa-eeac-4cde-9a4f-8e33bb977dfc"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <text>
                  <paragraph>Because of its short term usage no carcinogenicity, mutagenicity, or reproductive performance studies have been conducted with esmolol.</paragraph>
               </text>
               <effectiveTime value="20230915"/>
            </section>
         </component>
         <component>
            <section ID="ID_BBB5B541-BE1F-4EC8-B116-90E57A0A3532">
               <id root="39af51e1-ee86-4fcb-b3bd-96d402807d84"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Supraventricular Tachycardia:</content>
                     </content> In two multicenter, randomized, double-blind, controlled comparisons of esmolol hydrochloride injection with placebo and propranolol, maintenance doses of 50 to 300 mcg/kg/min of esmolol hydrochloride injection were found to be more effective than placebo and about as effective as propranolol, 3-6 mg given by bolus injections, in the treatment of supraventricular tachycardia, principally atrial fibrillation and atrial flutter. The majority of these patients developed their arrhythmias postoperatively. About 60-70% of the patients treated with esmolol hydrochloride injection developed either a 20% reduction in heart rate, a decrease in heart rate to less than 100 bpm, or, rarely, conversion to normal sinus rhythm and about 95% of these patients did so at a dosage of 200 mcg/kg/min or less. The average effective dosage of esmolol hydrochloride injection was approximately 100 mcg/kg/min in the two studies. Other multicenter baseline-controlled studies gave similar results. In the comparison with propranolol, about 50% of patients in both the esmolol hydrochloride injection and propranolol groups were on concomitant digoxin. Response rates were slightly higher with both beta blockers in the digoxin-treated patients.</paragraph>
                  <paragraph>In all studies significant decreases of blood pressure occurred in 20-50% of patients, identified either as adverse reaction reports by investigators, or by observation of systolic pressure less than 90 mmHg or diastolic pressure less than 50 mmHg. The hypotension was symptomatic (mainly hyperhidrosis or dizziness) in about 12% of patients, and therapy was discontinued in about 11% of patients, about half of whom were symptomatic. Hypotension was more common with esmolol hydrochloride injection (53%) than with propranolol (17%). The hypotension was rapidly reversible with decreased infusion rate or after discontinuation of therapy with esmolol hydrochloride injection. For both esmolol hydrochloride injection and propranolol, hypotension was reported less frequently in patients receiving concomitant digoxin.</paragraph>
               </text>
               <effectiveTime value="20230915"/>
            </section>
         </component>
         <component>
            <section ID="ID_9587E545-F3B5-4C27-81C3-6CF473DBD754">
               <id root="37d42056-cf58-4961-a1d2-8db45f597b78"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <effectiveTime value="20250227"/>
               <component>
                  <section ID="ID_6ad279b8-7616-44e1-8818-1cc05aa349a2">
                     <id root="5d92e29c-08f2-4b51-98ae-2ae11a02fd86"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied </title>
                     <text>
                        <paragraph>Esmolol Hydrochloride Injection, 100 mg/10 mL (10 mg/mL) is supplied as:</paragraph>
                        <paragraph>NDC 67457-182-10<br/>carton containing 10 x 10 mL single-dose vials</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ab9fe4c2-2d2e-4b37-b635-e45da67e8c59">
                     <id root="0afb5828-3011-4cc5-856b-0c3a25f85531"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.2 Storage </title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Avoid excessive heat.</content>
                        </paragraph>
                        <paragraph>Discard unused portion.</paragraph>
                     </text>
                     <effectiveTime value="20250227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_07A0D471-306F-4194-B8DE-9ADD5A5583A8">
               <id root="65423189-e454-41d0-9f6f-4aa721766d8e"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Physicians should inform patients of the risks associated with esmolol hydrochloride injection: </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>The most common adverse reactions are symptomatic hypotension (hyperhidrosis, dizziness) and asymptomatic hypotension.</item>
                     <item>
                        <caption>•</caption>Inform patients or caregivers that there is a risk of hypoglycemia when esmolol is given to patients who are fasting or who are vomiting. Monitor for symptoms of hypoglycemia <content styleCode="italics">[see <linkHtml href="#ID_388a6243-25d3-4a74-802e-fdb1463884b4">Warnings and Precautions (5.6)</linkHtml>]</content>.</item>
                  </list>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">Mylan Institutional LLC<br/>
                     </content>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">Mylan Institutional<br/>
                     </content>Galway, Ireland</paragraph>
                  <paragraph>50103382</paragraph>
                  <paragraph>Revised: 2/2025<br/>MI:ESMOIJ:R6</paragraph>
               </text>
               <effectiveTime value="20250227"/>
            </section>
         </component>
         <component>
            <section ID="ID_D9D35592-6DD7-4043-8CB1-6BF2AC768DE5">
               <id root="661243bb-e4dd-4844-ad6e-5f461564e3dd"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mg/10 mL </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 67457-182-10</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Esmolol <br/>Hydrochloride</content>
                     <br/>
                     <content styleCode="bold">Injection<br/>100 mg/10 mL</content>
                     <br/>(10 mg/mL)</paragraph>
                  <paragraph>
                     <content styleCode="bold">For Intravenous Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only     10 x 10 mL Single-Dose Vials</content>  </paragraph>
                  <paragraph>Contains no preservatives.<br/>Discard unused portion.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Each mL contains:</content> 10 mg Esmolol Hydrochloride, USP and Water for Injection. Buffered with 1.688 mg Sodium <br/>Acetate Anhydrous (equivalent to 2.8 mg Sodium Acetate Trihydrate) and 0.546 mg Glacial Acetic Acid. <br/>Sodium Hydroxide and/or Hydrochloric Acid added for pH adjustment. pH range is 4.5 to 5.5.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Usual Dosage:</content> See accompanying prescribing information.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Protect from freezing.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Avoid excessive heat.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Avoid contact with alkalies. Do not use if discolored or if a precipitate is present.</content>
                  </paragraph>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">Mylan Institutional LLC</content>
                     <br/>Morgantown, WV 26505 U.S.A.</paragraph>
                  <paragraph>Manufactured by:<br/>
                     <content styleCode="bold">Mylan Institutional</content>
                     <br/>Galway, Ireland</paragraph>
                  <paragraph>MI:182:10C:R6</paragraph>
                  <paragraph>
                     <content styleCode="bold">Mylan.com</content>
                  </paragraph>
                  <renderMultiMedia ID="id-949166458" referencedObject="A4AACBEB-1715-46F7-8FDB-8FD5729C75D6"/>
               </text>
               <effectiveTime value="20230915"/>
               <component>
                  <observationMedia ID="A4AACBEB-1715-46F7-8FDB-8FD5729C75D6">
                     <text>Esmolol Hydrochloride Injection 100 mg/10 mL Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>